to market faster. The company is also expanding its ISO 9001:2015 manufacturing capacity, which will be completed by mid-2025, to support more than $100 million in annual revenue and to demonstrate readiness to meet customers' demands as they scale...
Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan"). The stock options were approved on January 2, 2025 and were material to the employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock...
Executive Officer of ADC Therapeutics. "We look forward to completing enrollment of dose expansion in the first half of 2025 and plan to engage with regulatory authorities on the path forward as data including additional patients with longer...
Lodowski, Managing Director of Petauri Evidence, has been recognized as one of MM+M's esteemed 40 Under 40 honorees for 2025. Amanda Peterson, Vice President of Petauri Kinect, was also nominated. This annual award celebrates leaders from a range...
tumors with unmet medical needs. It is set to advance to its first U.S. IND submission and first patient dosing in 2025. As a monotherapy, PLT012 demonstrates remarkable anti-tumor efficacy in both immune 'hot' and 'cold' tumor models with a...
patients. An upcoming clinical trial for ST-001 targeting small cell lung cancer (SCLC) is anticipated to commence in Q2 2025. About ST-001: SciTech's lead drug candidate, ST-001 nanoFenretinide, is a patented nanoparticle formulation of...
in the lives of patients with ALS and are eager to move forward with our next clinical trial of NUZ-001 in early 2025." Impact on ALS Therapy and the Market: The ability of NUZ-001 to target TDP-43 aggregation and repair motor neuron function...
innovative drug therapies, today announced that it has received a PDUFA (Prescription Drug User Fee Act) date of June 2, 2025, for its LipidRescue Kit. If approved, the kit will treat LAST with the rapid and accurate infusion of a...
were transitioned to an expanded access protocol, and a report out of the PRECISION1 trial is expected to be provided in 2025. The Phase 2 trials of nab-sirolimus for advanced or recurrent endometrioid-type endometrial cancer (EEC) and...
generalized Myasthenia Gravis (gMG) and Thyroid Eye Disease (TED), with topline results expected in the first quarter of 2025 and first half of 2025, respectively. Additionally, HanAll, in collaboration with NurrOn Pharmaceuticals and Daewoong...
3 Study of Participants with Biochemical Recurrence of Prostate Cancer), is expected to begin patient recruitment in early 2025. The AMPLIFY trial will be a non-randomised, single-arm, open-label, multi-centre, Phase III diagnostic clinical trial...
and Fycompa in October 2024, and plans to expand activities to include Lenvima and anticancer agent Halaven from April 2025. Moreover, an application for Alzheimer’s disease treatment lecanemab has been submitted for review in Saudi Arabia. Saudi...
of Phase 2 in the next few months. We also expect to see the full Phase 1 results presented at a scientific meeting in 2025." "The available science increasingly highlights that fixed dosing at fixed intervals is unlikely to be optimal. Front...
as well as for our employees and business partners.” Financial details of the transaction were not disclosed. In FY2025, Bruker Biosensors expects additional revenues greater than $5 million from the DBS acquisition, with no material EPS impact....
for a healthy life." The study is set to start December 2024 at the nuHx headquarters in West Palm Beach and conclude May 2025 with published study results to follow. nuBioAge and its partner network will continue to pioneer unique studies like...
tissue and the validation of the immunological mechanism of action of the vaccine. The trial is expected to commence in 2025 and is projected to last approximately two to three years. Immunological responses to the vaccine will be made available as...
Vaxxas’ novel HD-MAP as well as through conventional needle and syringe. Initial results from the trial are expected in 2025 and will be provided to BARDA and published by Vaxxas and its clinical collaborators. "Global pandemic threats require the...
The NDA has been granted priority review, with a Prescription Drug User Fee Act (PDUFA) action date of January 29, 2025. "We are grateful to the patients, families, and physicians who participated in the studies that supported this new drug...
in a timely, safe and convenient way.” This year, the CDC recommends everyone ages 6 months and older receive updated 2024-2025 COVID-19 and flu vaccines, with rare exceptions. The CDC says that the concurrent administration of both vaccines is...
CVS Health® announced that the updated 2024-2025 COVID-19 vaccines and flu vaccines are available at CVS Pharmacy® and MinuteClinic® locations nationwide. Walk-ins are being accepted at CVS Pharmacy and the company's digital vaccine scheduler has...
